Blue Horseshoe Stocks: CGC Review & More

Canopy Growth Corp. CGC

We are incredibly proud of our alert on CGC a few weeks ago. The company had just seen its large investor, beverage behemoth Constellation Brands (STZ) had increased its stake Canopy by more than $4B.

This was a key factor in our formulation of the idea to track the CGC 09/21 $30-40 Calls, which we presented to our readers on the morning of August 15th. At the time, CGC stock was trading at a low of 29.05. The bull run which followed has been an absolute thing of beauty. This morning in the premarket, CGC stock has traded for as much as 57.05, marking a rise of 96% in a matter of three weeks.

That incredible move up has facilitated some unbelievably large gains in our designated call contracts. Their overall ranges and possible gains over that time span are as follows:

$30 Calls – Range: 1.76-21.82 – Max Gain: 1140%
$35 Calls – Range: .56-17.30 – Max Gain: 2989%
$40 Calls – Range: .16-12.30 – Max Gain: 7587%

Fun Fact: The purchase of ONE contract for $16 at the $40 strike point on the day of our initial alert, would have been worth $1214 at its highs this morning!  Cheers to anyone who has gotten even a piece of that action!
__________

Added Note: Canopy Growth is of course a cannabis related stock, so while we’re on the subject, here’s watchlist of lower priced pot plays to also watch as we head into autumn, traditionally one of the best times of year for the cannabis sector as a whole.

NXTTF, MYMMF, APHQF, RVVTF, TBPMF, SPRWF, INSY, CRON


Extended Watchlist:
NBEV, VCEL, SNES, CHFS, CDNA, VRA

Blue Horseshoe Stocks: TSN Recap & More

Tyson Foods Inc. TSN – Update

We started the week off yesterday by formulating some options ideas for TSN. The company had a mixed earnings call, with a beat on Q3 profits, and a miss on sales. We pointed to the technical setup of the chart as our primary reason for being interested, and as it turns out we called the bottom perfectly.

We came up with a short and longer term set of ideas, and while we may yet come back to the long terms, we are looking at the weekly calls we designated today after some solid performances. Those were the TSN Weekly $58-59.50 Calls, and all but the $58′s produced double-bag gains on the session.

$58.50 Calls – Range: .90-2.25 – Max Gain: 150%
$59 Calls – Range: .80-1.68 – Max Gain: 110%
$59.50 Calls – Range: .75-1.50 – Max Gain: 100%



Fresh Options Ideas

Our success with options over the past several weeks has been so pronounced, we see absolutely no reason to stop now, especially being in the thick of another earnings season. We’ve got another pair of earning related options ideas to bring to the table today.

Etsy, Inc. ETSY Weekly $40-50 Calls
Zillow Group, Inc. Z Weekly $48-49 Calls


Extended Watchlist:
TIS, NPTN, RNG, ACRX, MNK, EKSO, VCEL, TWLO

Blue Horseshoe Stocks: IDXG Update & More

Interpace Diagnostics Group, Inc. IDXG

We tracked IDXG last week over a couple of stellar sessions that led to a swing of more than 400%, cautioning that a dip-and-rip could be in the cards after seeing such a volatile move to the upside.

That’s exactly what we’ve seen in the past couple of days, as IDXG came down to find support at the .865 level, and in the ensuing three sessions it’s been steadily registering higher highs and higher lows, getting back to 1.25 yesterday (+45%).

We’ll continue to follow this story, which kicked off with the revelation that Aetna would cover Interpace’s ThyraMir™ test for its 46 million insured members. (>>View PR)


Experience Art & Design, Inc. EXAD

We had EXAD tagged in yesterday’s premarket report and this subpenny play produced a moderate run to kick off the session, even as the larger markets were struggling with the Fed rate hike announcement.

From an early low of .0023, the stock took just the first hour of trading to find its way up to a high of .0038, for a 65% pop. IDXG hung around that level until around lunchtime, and it did come back down to its daily low toward the close, so we’ll be looking for the possibility of a rebound.


Catalyst Biosciences, Inc. CBIO

We’re also interested in following the activity of CBIO today, which is gapping up in the premarket to the tune of more than 100% and looks like it could be lining up to have a big day. We’ll want to make sure it holds above its 50DMA (.80) on any pullbacks, but if it can breach past its 200DMA of 1.31, things could get very interesting.

News broke yesterday via an 8-K filing that CBIO had entered into a definitive agreement with Wyeth LLC, (wholly-owned subsidiary of Pfizer Inc.) to transfer exclusive rights to research, develop, manufacture and commercialize Factor VIIa variants, CB 813a and CB 813d, as well as transferring the investigational NDA to CBIO as well. (>>View Filing)



Fresh Options Idea: 
Transocean, Inc. RIG $15 and $14.50 Puts


Extended Watchlist:
VCEL, NWBO, BCLI, BPMX, DLOV, PPMT